Toggle menu

HighSTEACS

Start date:
June 2014
End date:
March 2017
Co-ordinated by:
University of Edinburgh & NHS Lothian

HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay

Research Team

EMERGE Research team
Cardiology Research Group

Aim

HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay. The primary endpoint is the one-year rate of cardiovascular death or recurrent myocardial infarction. Secondary endpoints include length of stay, unplanned coronary revascularisation, recurrent hospital admissions excluding ACS, bleeding events and non-cardiovascular death.  There is also a sub-study at the ED, RIE and in one site in NHS Greater Glasgow and Clyde.

Trial Design

Prospective stepped wedge cluster randomised controlled trial

Eligibility criteria (summary)

Patients who present to the Emergency Department with suspected heart disease

Chief Investigator

Dr Nick Mills

Consultant of Cardiology

Local PI

Professor Alasdair Gray

Director of EMERGE & Consultant in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

Hedda Nyhus

Senior Research Nurse

Bev Goldberg

AMU Senior Research Nurse

Megan McGrath

Senior Research Nurse

More EMERGE Trials

Auditting, monitoring and optimising the transfusion support given to trauma patients in Scotland

Read more

Code Red

Transfusion and Laboratory support in Trauma Group Code Red Audit

Molecular and cellular analysis of intracranial tumours

Read more

BRAINED

Molecular and cellular analysis of intracranial tumours

Intervention
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.

Read more

RAMPP trial

RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax